Intrommune
New York City, US · 2 known investors
Intrommune is a biotechnology company developing oral mucosal immunotherapy (OMIT), which delivers allergenic proteins through a specially formulated toothpaste to treat peanut and other food allergies. Its products target patients and families managing food allergies, spanning early allergen introduction in at-risk children and treatment options for those living with food allergy.
BiotechHealthtech
Founders & leadership
MN
Michael NelsonCEO & Board Member
WE
William E. BergerHead of Medical Affairs
CR
Christopher R. SchusterChief Financial Officer
NM
Nandini MurthyHead of Regulatory
RF
Ray ForslundHead of Chemistry, Manufacturing and Controls
MM
Miles McLennanHead of Commercial & Clinical Operations
Investors · 2
Competitors · 7
by search overlapInimmune8 shared keywordsInimmune is a clinical-stage biotech company that discovers and develops immunotherapies based on innate immune modulation, including Toll-like receptor agonists, to treat inflammatory conditions such as allergy, cancer, and autoimmune disease. Its lead program, INI-2004, is an intranasal TLR4 agonist in Phase 2 trials for allergic rhinitis, alongside INI-4001, a TLR7/8 agonist in Phase 1 oncology trials, plus pre-clinical vaccine adjuvant work.
NexImmune8 shared keywordsNexImmune is a biotechnology company developing antigen-directed immunotherapies based on its proprietary AIM nanoparticle platform, which mimics dendritic cell signaling to activate antigen-specific T cell responses. Its programs target oncology, autoimmune disorders, and infectious disease using formats including adoptive cell therapy (AIM ACT) and direct injection (AIM INJ).
Evommune8 shared keywordsEvommune develops therapies targeting the underlying sources of chronic inflammatory diseases, aiming to provide underserved patient populations with more than symptomatic relief. The company runs discovery and development programs with a focus on immunology.
Primmune Therapeutics7 shared keywordsPrimmune Therapeutics develops PRTX007, an orally administered, systemically active TLR7 agonist that activates interferon-associated innate immune pathways for use in cancer immunotherapy. The candidate is being developed for oncology applications, including combination with immune checkpoint inhibitors and neoadjuvant/adjuvant settings, and has been tested in two Phase 1 studies in healthy volunteers.
Avammune6 shared keywordsAvammune is a drug discovery company developing novel therapeutics for hard-to-treat solid tumors using computational chemistry, immunology, and targeted radiotherapeutics. The company focuses on converting immunologically cold tumors into responsive ones and identifying new cancer dependencies as therapeutic targets.
Inmune Bio6 shared keywordsINmune Bio is a clinical-stage biotechnology company developing immunotherapies, including XPro1595, aimed at treating neurodegenerative and psychiatric diseases through a biomarker-directed approach. The company works on translating inflammatory therapies into clinical treatments for neurologic and other diseases.
Immunome6 shared keywordsImmunome is a clinical-stage oncology company that discovers and develops targeted cancer therapies, with a focus on antibody-drug conjugates (ADCs). Its pipeline includes varegacestat (a gamma secretase inhibitor for desmoid tumors), IM-1021 (a ROR1-targeted ADC), and IM-3050 (a FAP-targeted radioligand), aimed at addressing high unmet need in cancer treatment.
Companies competing with Intrommune for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Intrommune do?
- Intrommune is a biotechnology company developing oral mucosal immunotherapy (OMIT), which delivers allergenic proteins through a specially formulated toothpaste to treat peanut and other food allergies. Its products target patients and families managing food allergies, spanning early allergen introduction in at-risk children and treatment options for those living with food allergy.
- Who are Intrommune's investors?
- Intrommune's investors include Red Bear Angels, Robin Hood Ventures.
- Where is Intrommune headquartered?
- Intrommune is headquartered in New York City, US.